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Abstract  
Introduction: Hearing loss affects communication, compromising quality of 
life, and is therefore associated with social costs as well as the economic costs of 
medical treatment or hearing aids (3). Magnesium treatment has been repeatedly 
shown to reduce the incidence of both temporary and permanent noise-induced 
hearing loss and also the protective effects of magnesium on hearing loss is well 
established in animal studies  but in few human studies(3). 
 
Purpose:  We hypothesized that it might also improve the permanent threshold 
shift in patients with acute-onset hearing loss. So we want to investigate the 
benefit of magnesium supplement combined with standard treatment of sudden 
sensorineural hearing loss (SSNHL) patients. 
Methods: This study proposes a randomized, double- blind, placebo-controlled 
parallel trial to assess the efficacy and safety of a combination of corticosteroids 
and magnesium (400mg daily) in sudden hearing loss. Audiological testing 
comprising of pure tone audiometry and speech-in-noise testing will be 
performed. 
Results: By use of a mixed effects statistical model, the effects of magnesium 
compared to placebo intake will be assessed. 
Conclusion: Magnesium is a relatively safe and convenient adjunct to steroid 
treatment for enhancing the improvement in hearing, especially in the low-tone 
range, in patients with sudden sensorineural hearing loss. 
 
STUDY PROTOCOL 
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INTRODUCTION 
Sudden sensorineural hearing loss 
(SSHL) is the term used to describe 
the abrupt onset of hearing loss of at 
least 30 dB in three consecutive 
frequencies on a standard audiogram 
(1). Incidence of SSNHL ranges from 
5 to 20 patients per 100,000 per year; 
the mean overall age of affected 
patients is between 46 and 49 years, 
with the lowest incidence in the 20–
30 year age group and the highest in 
the 50–60 year age group. In general 
the incidence seems to be equally 
distributed between the sexes. It is 
generally a unilateral process 
(approximately 98%), and functional 
hearing recovery without treatment 
was observed in up to 65 percent of 
patients (12, 15). 
Although many theories have been 
proposed, the ultimate etiology 
remains unknown. Among the many 
proposed causes of this condition are 
viral infection and the resultant 
inflammation, breaks in Reissner’s 
membrane causing persistent 
depolarization of hair cells due to the 
disruption of the appropriate ion 
gradient(2), and vascular insult to the 
cochlea(4). Given that this condition 
is currently defined by clinical 
criteria, it may be that each of these 
mechanisms is responsible for a 
proportion of the total number of 
observed cases. 
The discovery that the formation of 
free radicals in the inner ear is a key 
factor in hearing loss (5–10) suggests 
that antioxidants may play a 
preventive or therapeutic role. 
Recently, several animal studies have 
suggested that antioxidants act 
synergistically with magnesium 
intake to prevent hearing loss (7, 10). 
Magnesium is known to reduce 
noise-induced vasoconstriction that 
occurs as a result of free radical 
formation (7,24–25). Few 
epidemiologic studies have shown a 
protective effect of magnesium intake 
on hearing loss (20, 25), and we 
know of no epidemiologic studies 
that have examined the potential joint 
effects of corticosteroids and 
magnesium. The most widely 
accepted therapy is the use of 
steroids, administered systemically or 
intratympanically, alone or in 
combination. 
The disadvantages of systemic 
treatment with steroids are well-
known long-term complications. (16-
19) 
The present article proposes a 
protocol for a clinical study 
consisting of a double-blind, 
randomized, placebo-controlled trial 
with a combination of standard 
corticosteroid therapy and Mg++ 
supplement in humans after sudden 
hearing loss. 
The present report will follow the 
guidelines expressed by Consolidated 
Standards of Reporting Trials 
(CONSORT)
 
 
SUBJECTS AND METHODS  
Design 
This study proposes a randomized, 
double-blind, placebo-controlled 
parallel trial. Participants need to 
experience a sudden hearing loss 
which must be proved by an audiologic 
test. The loss of hearing must be at 
least 30 db at three consecutive 
frequencies. The symptoms of hearing 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:36 EEST - 137.108.70.6
                                                                                                                          LARISA,    AUGUST 2015 
 
 Σελίδα 4 
University of Thessaly : Msc «Μεθοδολογία Βιοϊατρικής Έρευνας, Βιοστατιστική και Κλινική Βιοπληροφορική>> 
loss must have recent onset-24h.Each 
participant need to take the treatment 
(corticosteroids and Mg or placebo) for 
a month and an audiogram will be 
done almost weekly during the 
treatment protocols in both the groups. 
One at the start, one after the 5 days 
therapy with prednisone, one at the 
meantime and the last at the end of the 
whole therapy with magnesium. This 
study aims to investigate the combined 
effects of Corticosteroids and Mg2+ in 
sudden sensorineural hearing loss in 
adults. 
 
Recruitment 
We will recruit adults with sudden 
sensorineural hearing loss from August 
2015 until July 2017 that will be 
admitted to the ENT clinic department 
of Larissa University Hospital. In order 
to recruit a fair number of patients we 
will send e-mails to all the private ENT 
doctors of Thessaly that often come 
across with this entity, and we will 
endorse them to admit the patients to 
the hospital. In addition, at the stage of 
enrolment it will be determined which 
occasions the subjects will attend and 
test moments will be scheduled. The 
aim is to plan all treatments within the 
range of one month in order to reduce 
the risk of drop-out 
. 
Treatment protocol 
 
After screening for eligibility, patients 
consenting to enroll will be divided 
randomly in two groups. Both groups 
will be similar regarding age, gender, 
season of the year in which deafness 
occurred, presence of vestibular 
symptoms and tinnitus, therapeutic 
delay from initial symptoms to start of 
treatment, and initial hearing loss.  A 
group will receive a combination of 
corticosteroids and Mg++ and B group 
corticosteroids and a placebo drug. 
Each participant will receive the same 
dose of corticosteroids as standard 
treatment which is prednisone 1 
mg/kg/d x 5 d and a packet with a pill 
of 200mg Mg or placebo twice a day. 
The participants will receive the 5 days 
therapy at the ENT clinic and they will 
continue at home by receiving only 
magnesium or placebo for one month. 
In 50%, the packets contain a placebo 
pill with an identical appearance and 
weigh as Magnesium (similar color-
taste). All participants (as well as the 
researchers) will be blinded to the 
order of magnesium and placebo.  
Safety assessment 
Adverse events are defined as 
symptoms occurring after the 
administration of magnesium and 
corticosteroids or placebo that are not 
necessarily related to the intervention. 
Participants will receive telephone 
number to report adverse events during 
the study and will be urged to come to 
the clinic in case of serious adverse 
events.  
The criterion adopted in this study to 
assess a therapeutic effect was an 
average improvement of 10 dB on 
Audiograms. This criterion was the 
widest adopted in the recent analysis 
on argument published in English 
literature (16-19). 
 
Adherence assessment 
After discharged from the hospital the 
participants will be given 60 pills each 
in 60 closed envelopes. These 
envelopes will be requested at the end 
of the therapy in order to ensure that 
the participants take all the pills. 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:36 EEST - 137.108.70.6
                                                                                                                          LARISA,    AUGUST 2015 
 
 Σελίδα 5 
University of Thessaly : Msc «Μεθοδολογία Βιοϊατρικής Έρευνας, Βιοστατιστική και Κλινική Βιοπληροφορική>> 
Permitted and prohibited 
concomitant treatments 
 
The use of alcohol and tobacco is 
limited to a maximum of two alcohol 
consumptions and to two cigarettes 
daily. Other psychoactive drugs are 
strictly prohibited 
 
The study will be approved by the 
local Research Ethics Committee and it 
will be performed in accordance with 
the ethical standards laid down in the 
2000 Declaration of Helsinki as well as 
the Declaration of Istanbul 2008. 
Follow-up 
The patients will be followed-up for 
one month. Patients lost during the 
follow-up and with evidence of 
retrocochlear disease at MRI (i.e., 
vestibular schwannoma) will be 
excluded from the analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Inclusion criteria  
The inclusion criteria are as follows: 
 Hearing loss 30db at 3 consecutive frequencies 
 Willingness to take treatment  
 Age between 18 and 60 (males as well as females) 
 Recent onset of hearing loss ≤ 24h 
 No prior treatment  
 
Exclusion criteria 
The exclusion criteria are as follows: 
 Middle ear pathologies such as otitis media and the perforation of the 
tympanic membrane and history of such pathologies. 
 Previous episode of hearing loss 
 Known allergies for corticosteroids or Mg++ 
 Diabetes  
 Pregnancy  
 
 
 
Institutional Repository - Library & Information Centre - University of Thessaly
26/03/2018 13:04:36 EEST - 137.108.70.6
                                                                                                                          LARISA,    AUGUST 2015 
 
 Σελίδα 6 
University of Thessaly : Msc «Μεθοδολογία Βιοϊατρικής Έρευνας, Βιοστατιστική και Κλινική Βιοπληροφορική>> 
Figure 1.   
 
                             Randomization 
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Patient evaluation  
 
Thorough history, otoscopy, bedside 
peripheral vestibular system 
examination, pure tone 
audiometry(repeated weekly), and MRI 
of internal auditory canal and 
cerebello-pontine angle. History 
detailed: onset of hearing loss, 
ontological symptoms related with 
hearing loss, drugs consumed in the 
past few days, and presence of others 
systemic diseases. The bedside 
examination was done by spontaneous 
and positional nystagmus, Romberg 
test, Unterberger test, Halmagyi test, 
and Head shaking test. 
 
Randomization  
 
The production of the corticosteroids 
with magnesium and placebo packets 
as well as the randomization of the 
ABAB protocol will be performed by 
an independent pharmacist. The 
packets of medicines and placebos will 
be labeled with a number 
corresponding with the numbers on the 
forms. The randomization file will be 
put into a sealed envelope and retained 
in a safe at the pharmacy. The 
randomization table will not be 
available for assessment by anyone 
else involved in the study. At the end 
of the study the envelope will be 
requested. 
 
 
 
Sample size calculation and 
statistical analysis 
A power approach calculation was 
performed in order to make an 
estimation of the sample size needed to 
detect significant differences in the 
audiograms between the experimental 
and control group. A two-independent 
groups test in which an α-level of 0.05 
and a nominal power of 90% will be 
used.  A 10-dB average difference in 
hearing outcome between treatments 
will be defined as clinical important. 
Standard deviation for the comparison 
is known to be equal to15db between    
the pre- and post-therapy 
measurements on the audiogram (taken 
into consideration the literature), a 
calculation showed a requirement of at 
least 48 participants. Because of the 
potential loss we add 10% more. So we 
need at least 53 participants. We will 
recruit 54 patients 27 in each arm. 
All data in this trial will be assessed 
with SPSS Statistics version 21.0. 
Because multiple correlated 
measurements will be performed in the 
same participants, a mixed effects 
model will be applied. This analysis is 
preferable over more traditional 
approaches such as repeated measures 
analysis of variance (ANOVA) 
because of the advantages to deal with 
missing values. 
 
 
RESULTS 
 
Outcomes  
The primary outcome measure will be 
the evaluation of a significant average 
difference in test results of the 
Audiological testing (audiometry and 
speech-in-noise tests) when comparing 
the placebo results to the medicine 
trials. 
 
Main outcome measures 
 
Pure tone audiometry   Pure tone 
liminiar audiometry will be performed 
according to the current clinical 
standards using a two-channel AC40 
Audiometer in a silent room. Air 
conduction thresholds will be 
measured under headphones at 125 Hz, 
250 Hz, 500 Hz, 1 kHz, 2 kHz, 4 kHz 
and 8 kHz. When air conduction 
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thresholds between 250 Hz and 4 kHz 
exceed normality levels of 20 dB HL, 
the bone conduction threshold will be 
measured on ,250 Hz, 500 Hz, 1kHz, 
2kHz and 4kHz in order to make a 
distinction between conductive and 
sensorineural hearing loss. 
 
 
Secondary outcome measures 
 
Speech discrimination testing Speech 
discrimination, as opposed to speech 
sensitivity, is the person's ability to not 
only hear words but to identify them. 
The procedure includes presentation of 
50 selected monosyllabic words at an 
easily detectable intensity level. The 
speech discrimination score (SDS) is 
the percentage of words correctly 
identified. Pathology of the inner ear, 
auditory nerve, and/or central auditory 
pathways can affect this score. The 
ability of an individual to discriminate 
speech is not well predicted by the 
pure-tone audiogram. An individual 
may hear a sound well enough, but the 
neural signals may be altered to the 
extent that the sound is unintelligible.  
Individuals suffering only a conductive 
hearing loss will be able to identify 
words if the sound is loud enough. For 
persons with sensorineural hearing 
loss, there is a marked drop in the 
score without a proportionate loss of 
pure-tone or speech sensitivity.  
Data and safety monitoring 
Monitoring will be conducted for 
quality control. Investigators will also 
be convened to discuss practical issues 
that might be encountered, such as 
dealing with serious adverse events, 
revising the protocol, and addressing 
certain important issues that might be 
raised by investigators and 
participants. We define adverse events 
as unintended signs, symptoms, or 
disease occurring after treatment that 
were not necessarily related to the 
intervention. The safety assessment 
will be based primarily on the 
frequency of adverse events, which 
included all serious adverse events. 
Information regarding adverse events 
was summarized by presenting the 
number and percentage of participants 
experiencing any adverse events. 
Ethics  
All procedures that will be followed 
will be in accordance with the ethical 
standards of the responsible committee 
on human experimentation (institution 
and national) and with Helsinki 
Declaration of 1975, as revised in 
2000.Written consent will be obtained 
from each participant. 
 
Dissemination policy 
According to the Standard Protocol 
Items: Recommendations for 
Interventional Trials(SPIRIT) 
guidelines, the authors declare that data 
that break the blind will not be 
presented prior to the release of 
mainline results. The breaking of the 
blind will occur at the end of the study. 
A clinical article will be written on the 
primary (including also secondary) 
outcomes of the study and results will 
be disseminated regardless of the 
magnitude or direction of effect. The 
present trial is not industry-initiated. 
As such, there are no publication 
restrictions imposed by sponsors. In 
addition, a full study report, 
anonymized participant- level dataset 
and statistical code for generating the 
results will be made publicly available 
no later than 3 years after the 
termination of the study for sharing
                                                                      purposes. 
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CONCLUSION  
 
Several medical treatment regimens are 
available to treat SSNHL, either in 
combination or alone. There is no 
universally accepted treatment for 
SSNHL. In fact, treatment itself is 
controversial since the rate of 
spontaneous recovery for SSNHL is 
often comparable to that reported for 
treated patients. Mattox and Simmons 
reported that the spontaneous recovery 
rate in SSNHL was 65% (12). 
Recently, Cinamon et al. conducted a 
prospective double-blind placebo-
controlled study including steroid, 
carbogen and placebo (23). Results 
revealed no significant difference 
between the treatment and placebo 
groups. 
The authors acknowledge the 
limitation of not including blood  
 
 
 
samples in the present protocol in order 
to control for naturally varying Mg++ 
levels in the individual. However, the 
investigators considered that it was 
very likely that the drop-out would be 
very high when participants needed to 
give a blood sample at every test 
moment.  
To our knowledge, this study is the 
first to combine steroids and Mg2+ as 
therapy for sudden hearing loss in 
adults performed in a randomized, 
placebo controlled trial. Furthermore, 
both participants and investigators will 
be blinded for the sequence of Mg and 
placebo. Thus, this would not influence 
on one hand the participants and on the 
other hand the investigators in 
performing the Audiological testing, 
limiting investigator bias as far as 
possible.
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